Dear Sir, I appreciate the opportunity for commenting on a Letter by Acerbi and coworkers concerning our past submission (http:// link.springer.com/article/10.1007%2Fs00701-015-2471-z).
Fluorescein is being investigated for fluorescence-guided resections of brain metastasis and gliomas [1] [2] [3] .
Eager to exploit the new potential of this application, our group is also exploring fluorescein, and has been exploring it for a while. However, in our hands we are having continuing problems using this method and are simply not observing the selectivity that we would desire.
In our experience with metastases ( Fig. 1 ) and malignant gliomas (Supplementary Video), significant fluorescein fluorescence is found after resection at the margins in obviously normal and perifocal edematous brain tissue despite all efforts to follow the guidance of Dr. Acerbi and coworkers using low doses (4 mg/kg) given with induction of anesthesia and performing surgery with the Zeiss Yellow 560 filter system. This confounds applicability. We find this worrisome. Our differing vantage points have obviously now generated a very lively discussion. Dr. Acerbi et al. feel (wrongly) accused, with accusations certainly not having been my intention. I highly respect their efforts to improve the surgical management of brain tumor patients. Nevertheless, I do critically reiterate that I believe the use of fluorescein outside of studies to be premature and requiring further investigation in a complex field in which histology, timing, dose, illumination, tissue perfusion, and edema play a role, with a marker of blood-brain barrier integrity that offers a tissue signal that is not simply binary. Others are critical as well [4, 5] 
